title: Soluble urokinase plasminogen activation receptor--An emerging new biomarker of cardiovascular disease and critical illness.
abstract: Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker, which has been shown to not only correlate with traditional biomarkers but also outperform CRP at prognosticating CVD. More clinical trials on suPAR is in the future research agenda.
authors.forename: Nicole B
authors.initials: NB
authors.lastname: Cyrille
authors.forename: Pedro A
authors.initials: PA
authors.lastname: Villablanca
authors.affiliation: Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic, Phoenix, AZ, USA.
authors.forename: Harish
authors.initials: H
authors.lastname: Ramakrishna
mesh_terms: D015415:Biomarkers / Q000097:blood*; D002318:Cardiovascular Diseases / Q000097:blood* / Q000175:diagnosis*; D016638:Critical Illness; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis; D006801:Humans; D055293:Receptors, Urokinase Plasminogen Activator / Q000097:blood*
chemical_list: D015415:Biomarkers; D055293:Receptors, Urokinase Plasminogen Activator